Results 221 to 230 of about 18,552,898 (302)

A Practical Guide to Implementing Real‐World Evidence as Primary Basis for Approval and Label Expansion

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
In June 2026, the FDA issued a revised draft guidance describing the circumstances in which one adequate and well‐controlled clinical investigation plus confirmatory evidence may satisfy the statutory substantial evidence standard for establishing efficacy and safety. Confirmatory evidence includes real‐world evidence (RWE).
Tracy J. Mayne   +2 more
wiley   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah   +4 more
wiley   +1 more source

A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies. [PDF]

open access: yesAnn Clin Transl Neurol
Laitinen AW   +7 more
europepmc   +1 more source

Antiviral Activity and Safety of Molnupiravir in Healthy Participants Inoculated With Influenza Virus: A Phase 2a, Randomized, Human Challenge Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Influenza viruses cause substantial global morbidity and mortality. Molnupiravir, an orally administered prodrug of β‐D‐N4‐hydroxycytidine, has broad activity against RNA viruses, including influenza. A phase 2a, randomized, two‐part human challenge trial in healthy adults (NCT05818124) was conducted to evaluate molnupiravir for influenza infection. In
Jesse Nussbaum   +11 more
wiley   +1 more source

Group-level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer's disease. [PDF]

open access: yesAlzheimers Dement
de Bruin H   +11 more
europepmc   +1 more source

Differential sensitivity to SHH signaling and neural crest‐mediated Gas1 expression regulate jaw size during development and evolution

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Developmental control of jaw size is crucial to prevent birth defects and facilitate evolutionary adaptation. We have shown that jaw size is established by neural crest mesenchyme (NCM), which are progenitor cells that migrate into the mandibular primordia and produce the jaws.
Zuzana Vavrušová   +5 more
wiley   +1 more source

Empirically Defining “Recurrent” Inappropriate Compensatory Behaviors: Differentiating Binge Eating Disorder From Bulimia Nervosa‐Spectrum Disorders

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective For multiple disorders, DSM‐5‐TR criteria include “recurrent” engagement in behaviors—for example, in the criteria for binge‐eating disorder (BED), “binge eating is not associated with the recurrent use of inappropriate compensatory behavior.”—without operationalizing how frequently a behavior needs to occur to be considered ...
Sophie R. Abber   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy